TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation June 22, 2026
Commonwealth of Massachusetts Honors Longwood Fund and Christoph Westphal with Governor’s Citation June 17, 2026
TScan Therapeutics and Cellares Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies June 4, 2026
Avenzo Therapeutics and Rallybio Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement June 1, 2026
Solu Therapeutics Granted FDA Fast Track Designation for STX-0712 for Treatment of Chronic Myelomonocytic Leukemia May 28, 2026
Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis May 27, 2026
